Patients with COVID‐19 are sometimes already being treated for one or more other chronic
conditions, especially if they are elderly. Introducing a treatment against COVID‐19, either …

Ritonavir, originally developed as HIV protease inhibitor, is widely used as a booster in
several HIV pharmacotherapy regimens and more recently in Covid-19 treatment (eg …

At the start of the coronavirus disease 2019 (COVID-19) outbreak in Europe, specific
antiviral treatments were based on previous experience with SARS-Cov-1 (severe acute …

Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A
low dose of ritonavir is added to other protease inhibitors to take advantage of potent …

Abstract Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects …

Objective To investigate the efficacy and safety of antiviral drugs in the treatment of
coronavirus disease 2019 (COVID-19). Methods All clinical trials of antiviral drug treatment …

With the introduction of combination antiretroviral therapy, HIV-1 infection is now considered
a treatable chronic infectious disease. Modern combination antiretroviral therapy consists of …

Abstract The coronavirus disease-19 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV2) has taken the world by surprise. To date, a …

The antiretroviral drug lopinavir/ritonavir has been recently repurposed for the treatment of
COVID-19. Its empirical use has been associated with multiple cardiac adverse reactions …

Introduction: The number of older HIV-infected people is growing due to increasing life
expectancies resulting from the use of antiretroviral therapy (ART). Both HIV and aging …